%0 Journal Article %T CD56 and CD11b Positivity with Low Smac/DIABLO Expression as Predictors of Chemoresistance in Acute Myeloid Leukaemia: Flow Cytometric Analysis %J Asian Pacific Journal of Cancer Prevention %I West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. %Z 1513-7368 %A Ibrahim, Abeer %A Zahran, Asmaa M %A Aly, Sanaa Shaker %A Refaat, Ahmed %A Hassan, Mohammed H %D 2018 %\ 11/01/2018 %V 19 %N 11 %P 3187-3192 %! CD56 and CD11b Positivity with Low Smac/DIABLO Expression as Predictors of Chemoresistance in Acute Myeloid Leukaemia: Flow Cytometric Analysis %K Chemoresistance %K CD56 %K CD11b %K Smac/DIABLO %K AML %R 10.31557/APJCP.2018.19.11.3187 %X Background: Resistance to chemotherapy is a major obstacle to curing acute myeloid leukaemia (AML), andseveral antigens are claimed to play primary roles in this resistance. Purpose: The aim of this study was to evaluatethe roles of CD56, CD11b and Smac/DIABLO gene expression levels as prognostic markers of the clinical outcome,response to chemotherapy and survival of AML patients. Materials and Methods: A cross-sectional observationalstudy was conducted on 60 naïve-AML patients who received induction therapy with mitoxantrone and cytarabinecombined with a high dose of cytarabine. The CD56,CD11b and Smac/DIABLO expression levels were assessed usingflow cytometry at diagnosis and were analysed for correlation with the possible associated risk factors, response tochemotherapy, and median duration of disease-free survival (DFS) and overall survival (OS). Results: The overall resultsrevealed that AML patients who exhibited positive expression for CD56 and CD11b had short median durations of DFSand OS.(P = 0.019, 0.006, 0.029 and 0.024, respectively). Additionally, low Smac/DIABLO expression had a negativeimpact on treatment outcome in terms of CR rate (p=0.012) and reduced DFS (p=0.000) and OS(p=0.000) values.Conclusions: CD56 and CD11b positivity and low Smac/DIABLO expression are important predictive factors forthe occurrence of chemoresistance, in addition to other risk factors, among AML patients. %U https://journal.waocp.org/article_73917_dc63d1e90d790a7d3c479ee4dda5bbb1.pdf